TNB-486 is under clinical development by AstraZeneca and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TNB-486’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TNB-486 is under development for the treatment of B-cell leukemia and B-cell non-Hodgkin’s lymphomas including high grade B cell lymphoma, B-cell Non Hodgkin lymphoma, marginal zone lymphoma (MZL), diffuse large B cell lymphoma, high-grade B-cell lymphoma, follicular lymphoma. The therapeutic candidates are bi-specific human heavy chain antibodies. They act by targeting immune checkpoint inhibitors. The drug candidates are developed based on high-affinity UniDab molecules from uniRat technology. UniRat is a transgenic rat that uses human immunoglobulin heavy-chain translocus to express a diverse repertoire of human heavy chain antibodies.
It was also under development for the treatment of mantle cell lymphoma.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of TNB-486’s drug-specific PTSR and LoA scores, buy the report here.